[ad_1]
If Pfizer’s human trials are successful, it will be possible to prescribe the pills early in the infection, to avoid complications and prevent the spread of the virus.
The medicine binds to an enzyme called “protease” to prevent the virus from reproducing. Protease inhibitor drugs have been successful in treating other types of viruses, such as HIV “AIDS” and hepatitis C “.
Pfizer Chief Scientist Michael Dolstein said: “Given how the Corona virus is mutating and its continued global impact, it looks like it will be important to find treatment options now, outside of it. ‘epidemic.”
He explained: “No unexpected problems have emerged in the study so far,” noting that it could lead to results in a matter of weeks, according to the US agency “Bloomberg”.
While the initial efficacy test will focus on the early stage of infection in people, Pfizer also plans to explore whether the drug works to protect healthy people who have been exposed to the coronavirus, such as limbs. family or roommates who live with someone.
Dolston added that the drug will likely be given twice a day for five days, considering it to represent a “potential game change.”
“If all continues to go well, Pfizer could start with a much larger phase two and three trial as early as the second quarter of 2021, which could allow it to apply for emergency use authorization from the Food. and Drug Administration by the end of the year, ”Dolstein said. This year, depending on the evolution of the epidemic.
Of note, Pfizer shares fell 1.3% to $ 35.55 at 12:36 p.m. New York time. The company’s share has grown by 32% over the past year.
[ad_2]
Source link
